Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic
Summary
SAN FRANCISCO--(BUSINESS WIRE)--Donnelley Financial Solutions (NYSE: DFIN), a leading risk and compliance company, today announced that Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health through therapeutic protection of the intestinal mucosal barrier, is working with DFIN to manage remote monitoring of their COVID-19 study. By allowing remote monitoring and source document verification of clinical study data, LBS has been able to continue its development activities without compromising the safety of patient volunteers, or that of company and CRO team members. “DFIN has revolutionized our management of the clinical trial monitoring process with their Venue data rooms,” said Inge K. Bear, Chief Development Officer at Leading BioSciences. “We have been able to reduce study costs, increase efficiency, maintain a safe work environment, and abide by all local, state and federal guidelines in the process. The Company’s initial focus is combatting the interruption of GI function (ileus) following major surgery to reduce recovery times and shorten patients’ length of stay in the hospital.